Acumen Research and Consulting recently published report titled “Orthostatic Hypotension Market and Region Forecast, 2022 - 2030”
LOS ANGELES, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Orthostatic Hypotension Market Size in 2021 was USD 715.2 Million, Market Value set to reach USD 1,422.9 Million growing at a CAGR of 8.1% from 2022 to 2030
Orthostatic Hypotension Market Overview
Orthostatic hypotension is a condition in which a person's blood pressure drops when they stand up after sitting or lying down. This happens because when a person stands up, gravity causes the blood to pool in the legs and away from the head, making it harder for the heart to pump enough blood to the brain. This can cause symptoms such as dizziness, lightheadedness, and fainting. Orthostatic hypotension can be caused by a variety of factors, including certain medications, dehydration, and certain medical conditions such as diabetes and Parkinson's disease. Treatment for orthostatic hypotension includes lifestyle changes such as drinking more water, increasing salt intake, and avoiding prolonged standing or sitting. Medications may be prescribed if the condition is caused by an underlying medical condition.
The orthostatic hypotension market size is driven by factors such as an increasing aging population, rising prevalence of chronic diseases such as diabetes and hypertension, and the growing awareness about the condition. Key players in the market include pharmaceutical companies such as Novartis, Pfizer, and AstraZeneca, which offer medications for the treatment of orthostatic hypotension. Medical device companies such as Medtronic and Zoll Medical also play a significant role in the market, offering devices such as pacemakers and defibrillators for the treatment of the condition.
The orthostatic hypotension market is expected to grow in the forthcoming years due to the increasing prevalence of the condition and the growing awareness about it. However, the market will also face challenges in terms of lack of awareness and high costs associated with treatment.
Request For Free Sample Report @ https://www.acumenresearchandconsulting.com/request-sample/3115
Orthostatic Hypotension Market Report Coverage:
| Market | Orthostatic Hypotension Market | |
| Orthostatic Hypotension Market Size 2021 | USD 715.2 Million | |
| Orthostatic Hypotension Market Forecast 2030 | USD 1,422.9 Million | |
| Orthostatic Hypotension Market CAGR During 2022 - 2030 | 8.1% | |
| Orthostatic Hypotension Market Analysis Period | 2018 - 2030 | |
| Orthostatic Hypotension Market Base Year | 2021 | |
| Orthostatic Hypotension Market Forecast Data | 2022 - 2030 | |
| Segments Covered | By Drug Type, By Diagnostics Test Type, By End-Use, And By Geography | |
| Orthostatic Hypotension Market Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa | |
| Key Companies Profiled | Amgen, Amneal Pharmaceuticals LLC, Apotex, Inc., Chelsea Therapeutics, F. Hoffman-La Roche, H. Lundbeck A/S, Mylan Inc, Novartis AG, Pfizer Inc., and Upsher-Smith Laboratories. | |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis | |
Orthostatic Hypotension Market Research Report Highlights and Statistics
- The global orthostatic hypotension market size is expected to reach a value of USD 1.423 billion by 2030, growing at a CAGR of 8.1% during the forecast period (2022-2030).
- The rising incidence of diabetes, hypertension, and heart diseases, increasing aging population and the growing number of elderly people with chronic diseases, increasing adoption of sedentary lifestyle and poor dietary habits are also contributing to the market growth.
- The market is segmented based on drug class, treatment type, distribution channel, and geography.
- North America holds the largest orthostatic hypotension market share, followed by Europe and Asia Pacific.
- The key players operating in the market include Novartis AG, Pfizer Inc., Merck & Co., Inc., Shire plc, and Novo Nordisk A/S, among others.
Trends in the Orthostatic Hypotension Market
- Aging population: As people age, their blood vessels become less elastic and less able to constrict when needed, leading to a greater risk of orthostatic hypotension.
- Chronic health conditions: chronic health conditions such as diabetes, hypertension, and heart disease can damage blood vessels and affect the body's ability to regulate blood pressure, increasing the risk of orthostatic hypotension.
- Medications: Certain medications, such as diuretics, antidepressants, and blood pressure medications, can cause orthostatic hypotension as a side effect.
- Dehydration: Dehydration can cause the blood volume to decrease, leading to a drop in blood pressure when standing up.
- Neurological disorders: Neurological disorders, such as Parkinson's disease and multiple system atrophy, can affect the nervous system's ability to regulate blood pressure, leading to orthostatic hypotension.
- Lifestyle factors: Certain lifestyle factors, such as a sedentary lifestyle and poor nutrition, can contribute to the development of orthostatic hypotension.
- The increasing obesity amongst the world population is also a risk factor for orthostatic hypotension, due to the increase in blood pressure and the pressure on the cardiovascular system.
Orthostatic Hypotension Market Dynamics
Orthostatic hypotension, also known as postural hypotension, is a condition in which a person's blood pressure drops significantly when they stand up from a seated or lying position. This condition is becoming increasingly common as chronic health conditions such as diabetes and hypertension become more prevalent.
There are several factors contributing to the growth of the orthostatic hypotension market share, including:
- Increasing geriatric population: As people age, their blood vessels become less elastic and less able to constrict when needed, leading to a greater risk of orthostatic hypotension.
- Rising prevalence of chronic diseases: Chronic health conditions such as diabetes and hypertension can damage blood vessels and affect the body's ability to regulate blood pressure, increasing the risk of orthostatic hypotension.
- Advances in technology: There have been recent technological advancements in the measurement and diagnosis of orthostatic hypotension, including non-invasive monitoring devices and mobile applications. This has led to a greater awareness of the condition and an increase in diagnosis and treatment.
- Government initiatives and increasing healthcare expenditure: The governments around the world are investing more on healthcare infrastructure and facilities to improve the health of the population which is expected to drive the growth of orthostatic hypotension market size.
- The increasing awareness of orthostatic hypotension among people and the healthcare professionals, is also contributing to the growth of the market.
Orthostatic Hypotension Market Growth Hampering Factors
- Lack of awareness: Many people with orthostatic hypotension may not be aware that they have the condition, and may not seek treatment. This can make it difficult for the market to grow.
- Limited treatment options: Currently, there are limited treatment options for orthostatic hypotension, which can make it difficult for patients to manage the condition effectively. This can also limit the growth of the market.
- Side effects of medications: Some of the medications used to treat orthostatic hypotension can have significant side effects, which can make it difficult for patients to comply with treatment.
- Cost: The cost of treatment can be a barrier to access for some patients, especially those without insurance or with high deductibles.
- Limited Research on the disease: lack of research can also be seen as a hindering factor in the growth of the market. As a relatively uncommon condition, there has not been a great deal of research into orthostatic hypotension, which makes it difficult to understand the underlying causes of the condition and to develop new treatments.
- Stigma attached to the disease can also be a hindering factor in the growth of the market, patients might be hesitant to seek help due to fear of being labeled or stigmatized.
Check the detailed table of contents of the report @
https://www.acumenresearchandconsulting.com/table-of-content/orthostatic-hypotension-market
Market Segmentation
The market for orthostatic hypotension can be segmented based on different criteria, such as:
- Type of treatment: The market can be segmented into pharmacological and non-pharmacological treatments. Pharmacological treatments include medications that increase the amount of norepinephrine, while non-pharmacological treatments include physical therapy and lifestyle changes.
- End-user: The market can be segmented into hospitals, clinics, and home healthcare settings.
- Disease Stage: The market can be segmented into early stage and advanced stage of disease.
- Patients: The market can be segmented into children, adult, and elderly patients.
- Distribution Channel: The market can be segmented into hospitals, retail pharmacies, online pharmacies and others.
Orthostatic Hypotension Market Overview by Region
- North America: The North American orthostatic hypotension market share is the largest in the world due to the high incidence of the condition among older adults in the region along with increasing awareness of the condition, and the availability of new treatments.
- Asia-Pacific: The Asia-Pacific orthostatic hypotension market share is expected to grow at the fastest rate over the forecast period, due to vast aging populations in countries like China and Japan along with a huge population in India which is currently suffering from the obesity epidemic alongside rising cases of blood pressure issues.
- Europe: The European market for orthostatic hypotension is also expected to grow at a good pace given the aged population and high income earning countries of the region.
Buy this premium research report –
https://www.acumenresearchandconsulting.com/buy-now/0/3115
Orthostatic Hypotension Market Key Players
AstraZeneca, Novartis AG, Pfizer Inc., Merck & Co. Inc., Sanofi, Takeda Pharmaceuticals, Johnson & Johnson ,GlaxoSmithKline plc ,AbbVie Inc. ,Roche Holding AG ,Bristol-Myers Squibb Company ,Boehringer Ingelheim ,Daiichi Sankyo Co. Ltd. ,Teva Pharmaceutical Industries Ltd. ,Mylan N.V., Biogen, Sunovion Pharmaceuticals Inc.,Daiichi Sankyo Europe GmbH ,Alnylam Pharmaceuticals Inc.,CSL Behring LLC.
Browse More Research Topic on Healthcare Sector Related Reports:
The Global Neurotech Devices Market size was valued at USD 10,796 Million in 2021 and is projected to reach USD 34,761 Million by 2030, with a significant CAGR of 14.3% from 2022 to 2030.
The Global Sleep Tech Devices Market size was valued at USD 15,407 Million in 2021 and is estimated to reach the value of USD 60,955 Million by 2030, growing at a CAGR of 16.8% from 2022 to 2030.
The Global Tubeless Insulin Pump Market size was accounted for USD 1,066 Million in 2021 and is estimated to reach the market value of USD 6,027 Million by 2030, growing at a CAGR of 21.7% from 2022 to 2030.
About Acumen Research and Consulting:
Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
For Latest Update Follow Us on Twitter , Instagram and LinkedIn
Contact Us:
Mr. Richard Johnson
Acumen Research and Consulting
USA: +13474743864
India: +918983225533
E-mail: sales@acumenresearchandconsulting.com
Via GlobeNewswire RSS Feed https://ift.tt/nQA3fxl